Blood test to screen for heart risk in fatty liver disease
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at a simple blood test (mean platelet volume, or MPV) to see if it can help predict heart attacks in people with fatty liver disease. If it works, doctors might use this test to identify at-risk patients earlier and prevent heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of fatty liver disease (MASLD).
- You may join this study if you have had a heart attack or unstable angina, or if you have fatty liver disease but no heart symptoms.
- You cannot join if you have other liver diseases like hepatitis or alcohol-related liver disease.
- You cannot join if you have blood disorders or take blood-thinning medications.
- You cannot join if you have an active infection, inflammatory disease, cancer, or serious kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether aspirin can help people with MASLD, a type of fatty liver disease linked to conditions like diabetes and obesity. It aims to see if aspirin can improve liver health without causing harm.
This study looks at how certain features of your metabolism affect a simple score (called the FAST score) in people with fatty liver disease (MASLD). It aims to help doctors better understand and manage the condition.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study looks at whether simple blood tests can help predict liver scarring (fibrosis) in people with fatty liver disease. If you join, you'll have a quick, non-invasive scan of your liver to check for fat and scarring.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study looks at heart health in people with fatty liver disease (MASLD) by measuring calcium in the heart's arteries with a special scan, to see if they are at risk for heart problems.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.